A5016643927- Prostate Cancer Diagnosis and Treatment
- Global Cancer Incidence and Screening
- Prostate Cancer Treatment and Research
- Health Systems, Economic Evaluations, Quality of Life
- Health Promotion and Cardiovascular Prevention
- Colorectal Cancer Screening and Detection
Prostate Cancer UK
2019-2024
To develop a consensus statement on current best practice of active surveillance (AS) in the UK, informed by patients and clinical experts.A was drafted basis three sources data: systematic literature search national international guidelines; data arising from Freedom Information Act request to UK urology departments regarding their AS; survey interview responses men with localized prostate cancer experiences views AS. The Prostate Cancer Expert Reference Group (ERG) AS then convened discuss...
Screening is not recommended for prostate cancer in the UK. Asymptomatic men aged ≥50 years can request a prostate-specific antigen (PSA) test following counselling on potential harms and benefits. There are areas of clinical uncertainty among GPs, resulting content quality varying.
Background The UK has an informed choice testing policy for prostate cancer. prostate-specific antigen (PSA) blood test is available free to any man aged ≥50 years who requests it and been of the harms benefits. This leads differences in PSA rates, which can exacerbate health inequalities. Aim To assess whether Prostate Cancer UK’s risk checker helps men at cancer make about test. Design & setting Mixed-methods study UK. Method In total, 1181 risk, their partners, clinical experts...